BTOG 2019 | Pembro continues to demonstrate OS benefit in first-line NSCLC: KEYNOTE-024 update

Martin Reck

Martin Reck, MD, PhD, of Hospital Grosshansdorf, Grosshansdorf, Germany, presents an updated overall survival (OS) and tolerability analysis from the Phase III KEYNOTE-024 trial (NCT02142738), which compared pembrolizumab monotherapy with standard chemotherapy in the frontline setting for advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression and without EGFR/ALK aberrations. Prof. Reck emphasizes how this longer follow-up showed that single-agent pembrolizumab continued to exhibit an OS benefit in this population. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

Share this video